Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Linezolid bulk supplier for pharma manufacturers

Linezolid 100 mg/5 mL Suppliers & Bulk Manufacturers

Available Forms: Oral Suspension

Available Strengths: 100 mg/5 mL

Reference Brands: Zyvox(US & EU)

Category: Critical Care

Linezolid is a potent antibiotic for resistant infections like MRSA and VRE. Available in 600 mg tablets, oral suspension, and 600 mg/300 mL IV infusion, it is sold under brands like Zyvox and Zyvoxid. Pharma B2B platforms offer bulk Linezolid sourcing for hospitals and critical care settings.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Linezolid is an oxazolidinone-class antibiotic used to treat multidrug-resistant Gram-positive infections, including MRSA and VRE. It is available in oral tablets (600 mg), oral suspension (100 mg/5 mL), and IV infusion (600 mg/300 mL), making it versatile for hospital and outpatient settings. In the US, Linezolid is marketed as Zyvox by Pfizer, with generic versions by Fresenius, Teva, and Hikma. In the EU, it is sold as Zyvoxid and through major generics by Sandoz, Mylan, and Accord. Pharma B2B platforms facilitate efficient bulk procurement of Linezolid for hospitals, ICUs, and infectious disease treatment centers.

Linezolid — third party manufacturing & bulk supply

Linezolid 100 mg/5 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Linezolid is supplied as Oral Suspension — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Linezolid listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Linezolid →
Back to Listing

Frequently Asked Questions

Linezolid is listed as Oral Suspension in 100 mg/5 mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Linezolid is referenced against Zyvox(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Linezolid

Strength:
600 mg

Form: Oral Tablets

Reference Brands: Zyvox(US & EU)

View Details
Linezolid

Strength:
600 mg/300 mL (2 mg/mL)

Form: IV Infusion

Reference Brands: Zyvox(US & EU)

View Details
Cefotaxime

Strength:
250 mg, 500 mg, 1 g, 2 g

Form: IV and IM Injection

Reference Brands: Claforan(US)

View Details
Colistimethate (Colistin)

Strength:
150 mg Colistin base activity (equivalent to 1 million IU)

Form: Intravenous (IV) Injection

Reference Brands: Coly-Mycin M(US); Colomycin(EU)

View Details
Regadenoson

Strength:
0.4 mg/5 mL

Form: injection (prefilled syringe)

Reference Brands: Lexiscan (USA)

View Details
Metaraminol

Strength:
10 mg/mL

Form: Injection

Reference Brands: Aramine (USA)

View Details
Plerixafor

Strength:
20 mg/mL

Form: Injection

Reference Brands: Mozobil (USA/EU)

View Details
Pentamidine Isethionate

Strength:
300 mg

Form: Injection / Inhalation solution

Reference Brands: Pentam (USA), Nebupent (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.